

What is the Comprehensive Care Sustainability Collaborative (CCSC)?



- CCSC is a quality improvement and cost management initiative sponsored by the National Hemophilia Foundation (NHF)
- The aim of CCSC is to provide payers with knowledge crucial for managing the high costs associated with hemophilia and to augment the sustainability of hemophilia treatment centers (HTCs) as centers of excellence

Benefits for Employers

- Total cost of care analysis and education on cost containment strategies
- Identification of key cost drivers and transparent strategic management tools to enable risk mitigation and drive significant savings
- Facilitated value-based dialogue between payers and the provider experts throughout the hemophilia treatment center (HTC) network of federally recognized centers of excellence; integrated medical home treatment for hemophilia and other rare bleeding or clotting disorders
- Contracting pitfalls identified and recommendations made

What is the Recommended Course of Action when an Employer Becomes Aware of Employees/Beneficiaries with Hemophilia?

- Engage NHF's payer team for early identification of strategies that will enable lowest total cost of care management
- Determine if hemophilia care is being delivered by an HTC
- Utilize risk mitigation strategies aimed at ensuring transparency and the cost effective delivery of the required specialty biologic drug treatments; which make up >85% of the total cost of care
- Be aware of the unintended consequences of copay assistance and accumulator adjustments programs
- Consider the potential of unintended consequences before applying an accumulator adjustment program as a one size fits all option to patients with hemophilia, who have no cheaper generic equivalents available and to best manage total cost of care, must be proactive, not reactive¹

For More Information and Resources go to www.CCSCHemo.com

The Value of Hemophilia Comprehensive Care – 6-minute video

Accumulator Adjustment Program Fact Sheet

Award Winning CCSC White Paper

Inhibitor Case Study

Have Questions or Want to Find Out How to Participate? Contact:

Kollet Koulianos, MBA
Senior Director Payer Relations
309.397.8431 | kkoulianos@hemophilia.org

References: 1. Soucie JM, et al. *Blood*. 2000;96:437-442.

Jointly sponsored by the



CCSC is supported by charitable donations from founding supporter, Takeda, and additional support from Bayer, BioMarin, Genentech, Inc., Hemophilia Alliance, Pfizer Inc., Sanofi Genzyme, and Spark Therapeutics.

© 2020 National Hemophilia Foundation. All rights reserved.